{"id":69852,"date":"2026-07-13T16:19:26","date_gmt":"2026-07-13T08:19:26","guid":{"rendered":"https:\/\/flcube.com\/?p=69852"},"modified":"2026-07-13T16:19:27","modified_gmt":"2026-07-13T08:19:27","slug":"abbisko-therapeutics-secures-fda-ind-clearance-for-pan-kras-inhibitor-absk211-targeting-broad-spectrum-of-kras-alterations-in-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69852","title":{"rendered":"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Abbisko Therapeutics Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2256:HKG\">HKG: 2256<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has cleared the <strong>Investigational New Drug (IND) application<\/strong> for <strong>ABSK211<\/strong>, an <strong>oral, highly potent and selective small-molecule pan-KRAS inhibitor<\/strong>, for the treatment of patients with <strong>advanced solid tumors harboring KRAS alterations<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND clearance<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ABSK211 (oral pan-KRAS inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors with KRAS alterations<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>13 Jul 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Initiation of Phase I clinical trial in U.S. patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This IND clearance represents a significant advancement in targeting one of oncology&#8217;s most challenging mutations, with ABSK211 demonstrating activity across multiple KRAS variants that have historically been considered &#8220;undruggable.&#8221;<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> ABSK211<\/li>\n\n\n\n<li><strong>Class:<\/strong> Oral, highly potent and selective small-molecule pan-KRAS inhibitor<\/li>\n\n\n\n<li><strong>Target Spectrum:<\/strong> Broad activity across multiple KRAS alterations including G12D, G12C, G12S, G12V, G13D, and KRAS wild-type amplification<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First-in-class pan-KRAS inhibitor with comprehensive coverage of major KRAS mutation subtypes<\/li>\n\n\n\n<li><strong>Developer:<\/strong> Independently developed by Abbisko Therapeutics<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">KRAS mutations occur in approximately 25% of all human cancers, making it one of the most frequently altered oncogenes. Despite decades of research, KRAS has remained largely undruggable until recent breakthroughs with allele-specific inhibitors like sotorasib (G12C-specific).<\/p>\n\n\n\n<h2 id=\"h-clinical-development-plan\" class=\"wp-block-heading\">Clinical Development Plan<\/h2>\n\n\n\n<h3 id=\"h-phase-i-trial-design\" class=\"wp-block-heading\">Phase I Trial Design<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Type:<\/strong> Open-label, dose-escalation and expansion study<\/li>\n\n\n\n<li><strong>Primary Objectives:<\/strong> Assess safety, tolerability, and determine recommended Phase II dose<\/li>\n\n\n\n<li><strong>Secondary Objectives:<\/strong> Evaluate efficacy, pharmacokinetics, and pharmacodynamics<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Advanced solid tumors harboring various KRAS alterations<\/li>\n\n\n\n<li><strong>Trial Sites:<\/strong> Multiple U.S. centers with potential expansion to international sites<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The broad spectrum of KRAS alterations targeted by ABSK211 could significantly expand the treatable patient population compared to allele-specific inhibitors currently available.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>KRAS Inhibitor<\/th><th>Target Specificity<\/th><th>Limitations<\/th><th>ABSK211 Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Sotorasib (Lumakras)<\/strong><\/td><td>G12C only<\/td><td>~13% of KRAS mutations<\/td><td>Pan-KRAS coverage<\/td><\/tr><tr><td><strong>Adagrasib (Krazati)<\/strong><\/td><td>G12C only<\/td><td>~13% of KRAS mutations<\/td><td>Pan-KRAS coverage<\/td><\/tr><tr><td><strong>ABSK211 (Abbisko)<\/strong><\/td><td>G12D, G12C, G12S, G12V, G13D, WT amplification<\/td><td>Under investigation<\/td><td>Comprehensive mutation coverage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">KRAS G12D alone accounts for approximately 40% of KRAS mutations in pancreatic cancer and 15-20% in colorectal cancer, representing substantial unmet medical need beyond the G12C population.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Paradigm Shift:<\/strong> Potential to move from allele-specific to pan-KRAS inhibition approach<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Could treat up to 80-85% of all KRAS-mutated cancers vs. 13% with current G12C inhibitors<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Oral administration enables convenient combination with other targeted therapies and immunotherapies<\/li>\n\n\n\n<li><strong>Global Leadership:<\/strong> Positions Abbisko as pioneer in next-generation KRAS inhibition<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Addresses multi-billion dollar market across multiple solid tumor indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The development of pan-KRAS inhibitors represents the holy grail of KRAS-targeted therapy, potentially offering a single agent solution for the majority of KRAS-driven cancers.<\/p>\n\n\n\n<h2 id=\"h-investment-amp-pipeline-context\" class=\"wp-block-heading\">Investment &amp; Pipeline Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity:<\/strong> KRAS-mutated cancers represent $10-15 billion annual market opportunity globally<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> Phase I data expected within 12-18 months<\/li>\n\n\n\n<li><strong>Competitive Window:<\/strong> Significant first-mover advantage in pan-KRAS space<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Strong clinical data likely to attract major pharmaceutical interest<\/li>\n\n\n\n<li><strong>Pipeline Leverage:<\/strong> Success validates Abbisko&#8217;s structure-based drug design platform for challenging targets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Abbisko&#8217;s focus on difficult-to-drug targets aligns with the company&#8217;s strategic positioning as an innovative oncology-focused biopharmaceutical company.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and funding availability.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[186,62,921],"class_list":["post-69852","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbisko-therapeutics","tag-clinical-trial-approval-initiation","tag-hkg-2256"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABSK211, an oral, highly potent and selective small-molecule pan-KRAS inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS alterations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69852\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABSK211, an oral, highly potent and selective small-molecule pan-KRAS inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS alterations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69852\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T08:19:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-13T08:19:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69852#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69852\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors\",\"datePublished\":\"2026-07-13T08:19:26+00:00\",\"dateModified\":\"2026-07-13T08:19:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69852\"},\"wordCount\":585,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abbisko Therapeutics\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2256\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69852#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69852\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69852\",\"name\":\"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-13T08:19:26+00:00\",\"dateModified\":\"2026-07-13T08:19:27+00:00\",\"description\":\"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABSK211, an oral, highly potent and selective small-molecule pan-KRAS inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS alterations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69852#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69852\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69852#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABSK211, an oral, highly potent and selective small-molecule pan-KRAS inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS alterations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69852","og_locale":"en_US","og_type":"article","og_title":"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors","og_description":"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABSK211, an oral, highly potent and selective small-molecule pan-KRAS inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS alterations.","og_url":"https:\/\/flcube.com\/?p=69852","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-13T08:19:26+00:00","article_modified_time":"2026-07-13T08:19:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69852#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69852"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors","datePublished":"2026-07-13T08:19:26+00:00","dateModified":"2026-07-13T08:19:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69852"},"wordCount":585,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abbisko Therapeutics","Clinical trial approval \/ initiation","HKG: 2256"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69852#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69852","url":"https:\/\/flcube.com\/?p=69852","name":"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-13T08:19:26+00:00","dateModified":"2026-07-13T08:19:27+00:00","description":"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABSK211, an oral, highly potent and selective small-molecule pan-KRAS inhibitor, for the treatment of patients with advanced solid tumors harboring KRAS alterations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69852#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69852"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69852#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbisko Therapeutics Secures FDA IND Clearance for Pan-KRAS Inhibitor ABSK211, Targeting Broad Spectrum of KRAS Alterations in Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69852"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69852\/revisions"}],"predecessor-version":[{"id":69853,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69852\/revisions\/69853"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}